UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 473,363 Shares of Zoetis Inc. $ZTS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Zoetis Inc. (NYSE:ZTS) by 10.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,924,988 shares of the company’s stock after selling 473,363 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Zoetis were worth $282,050,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Louisiana State Employees Retirement System purchased a new position in Zoetis during the 1st quarter valued at about $2,542,000. Wealthfront Advisers LLC grew its holdings in Zoetis by 80.2% in the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after purchasing an additional 33,873 shares during the period. Deutsche Bank AG grew its holdings in Zoetis by 19.1% in the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after purchasing an additional 891,921 shares during the period. Pincus Capital Management LP bought a new position in shares of Zoetis during the fourth quarter valued at approximately $2,109,000. Finally, Diamond Hill Capital Management LLC Investment Advisor increased its stake in shares of Zoetis by 21.5% during the second quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after purchasing an additional 629,974 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $76.99 on Tuesday. The business’s fifty day simple moving average is $75.59 and its two-hundred day simple moving average is $95.04. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $156.49. The company has a market cap of $31.81 billion, a price-to-earnings ratio of 12.68, a P/E/G ratio of 1.80 and a beta of 0.73.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on ZTS shares. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. JPMorgan Chase & Co. lowered their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Stifel Nicolaus dropped their target price on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Piper Sandler cut their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. Finally, BNP Paribas Exane reduced their price target on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $107.43.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.